Having been backed in the week before Christmas by a US Food and Drug Administration (FDA) panel by a slender margin of two votes, executives from AstraZeneca (LSE: AZN) and Merck & Co (NYSE: MRK) would not have been certain about the approval of Lynparza (olaparib) in a pancreatic cancer indication during their seasonal break.
But they might feel more free to enjoy their New Year’s Eve celebrations after the FDA announced Lynparza’s approval on Monday in this notoriously hard-to-treat patient group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze